In contrast, when the AD group was compared to the treatment groups, the p-Akt/Akt ratio and p-GSK3β/GSK3β ratio of protein expression were increased: AD+40 (p-Akt/Akt ratio: P < .001, p-GSK3β/GSK3β ratio: P = .003), AD+EX (p-Akt/Akt ratio: P < .001, p-GSK3β/GSK3β ratio: P = .001), and AD+40+EX (p-Akt/Akt ratio: P < .001, p-GSK3β/GSK3β ratio: P < .001). Here, AKT1 is linked to Alzheimer disease.